

S 4175

Pharmaceutical Supply Chain Defense and Enhancement Act

Congress: 116 (2019–2021, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Jul 2, 2020

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Jul 2, 2020)

Official Text: <https://www.congress.gov/bill/116th-congress/senate-bill/4175>

Sponsor

Name: Sen. Warren, Elizabeth [D-MA]

Party: Democratic • **State:** MA • **Chamber:** Senate

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Smith, Tina [D-MN]	D · MN		Jul 2, 2020

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Jul 2, 2020

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 S 4191	Related bill	Jul 2, 2020: Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.

Pharmaceutical Supply Chain Defense and Enhancement Act

This bill requires the Department of Health and Human Services (HHS) to enter into contracts with U.S. entities to manufacture certain critical drugs within the United States and otherwise addresses drug manufacturing.

HHS must periodically report to Congress a list of drugs that are critical to public health or national security. The Biomedical Advanced Research and Development Authority within HHS must enter into contracts for qualified U.S. entities to manufacture in the United States the drugs on this list (and ingredients for such drugs). The contracts must impose certain conditions, such as those requiring the manufacturing entity to (1) develop and maintain a redundancy risk management and continuity of business plan, and (2) commit to selling the drugs and ingredients manufactured under the contract at reasonable prices.

Beginning in FY2024, certain federal agencies (including the Department of Defense and the Bureau of Prisons) must, in procuring drugs on the HHS critical drugs list, give priority to high-quality drugs that are manufactured in the United States.

This bill also requires the Federal Trade Commission to submit annually to Congress a report on foreign investment in the U.S. pharmaceutical industry. The report must address, among other topics, the effect of the industry's reliance on foreign manufacturing.

Actions Timeline

- **Jul 2, 2020:** Introduced in Senate
- **Jul 2, 2020:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.